QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for
research use, a new tool in the fight against tuberculosis (TB),
the world’s leading infectious disease killer.
Building on QIAGEN’s ongoing efforts to support
global TB management and control, which include the leading
diagnostics test QuantiFERON-TB Gold Plus, the new panel enables
culture-free whole genome sequencing (WGS) directly from samples
such as sputum or cerebrospinal fluid. This innovation
significantly reduces the time to result and enables real-time
epidemiology of TB outbreaks, addressing a critical need in the
field of TB surveillance and control.
The QIAseq xHYB Mycobacterium tuberculosis Panel
represents a major advancement in solving the problem of bacterial
WGS from complex host samples, using next-generation sequencing
(NGS). It is designed against the seven major lineages of TB,
covering the full breadth of diversity. By eliminating the need for
a 4-to-6-week bacterial culture, the panel significantly
accelerates the process of obtaining results.
“The introduction of the QIAseq xHYB
Mycobacterium tuberculosis Panel reflects our ongoing commitment to
address global health challenges like TB and antimicrobial
resistance,” said Nitin Sood, Vice President, Head of the Life
Sciences Business Area at QIAGEN. “This innovative panel not only
streamlines the workflow for healthcare professionals and
researchers but also enables the real-time tracking of TB
outbreaks, a crucial aspect in combating the spread of this
devastating disease and managing the growing threat of
drug-resistant TB.”
“Innovative aspects of this workflow are the
whole genome analysis from clinical samples, avoidance of the
culturing delay, and inclusion of genetic diversity,” stated
Daniela Maria Cirillo, MD, PhD, Head of Emerging Bacterial
Pathogens Unit at IRCCS San Raffaele Scientific Institute, Milan,
Italy.
The QIAseq xHYB Mycobacterium tuberculosis Panel
also plays a vital role in the detection and management of
antimicrobial resistance (AMR), a growing concern in TB treatment.
The panel covers all AMR-related genes, allowing for the
identification of resistant TB strains, including
multidrug-resistant tuberculosis (MDR-TB), which is caused by
bacteria that do not respond to the most effective first-line TB
drugs.
Surveillance of TB, including drug-resistant
strains which occur in around 4% of all TB cases[1], helps track
the emergence and spread of resistance. This provides essential
information for updating treatment guidelines and spurs research
and development efforts focused on new TB treatments and diagnostic
methods, ultimately improving patient outcomes.
TB is a contagious bacterial infection,
primarily spread by the coughing of patients with the active
pulmonary form of the disease. The WHO estimated that there were
more than 10 million new cases of active TB worldwide and 1.3
million deaths in 2022.
QIAGEN is committed to supporting TB management
worldwide. Its leading diagnostics solution, QuantiFERON-TB Gold
Plus, accurately detects latent TB infection by identifying
interferon-gamma released by T-cells in response to TB-specific
antigens. This one-visit test outperforms the century-old,
two-visit TB skin test (TST). Over 100 million QuantiFERON-TB tests
have been used worldwide to detect TB, and over 1,500 studies have
been published using this test. One in four people worldwide are
believed to have latent TB infections, with 5-10% of them expected
at some point to develop active TB. The CDC and WHO endorse the use
of QuantiFERON-TB Gold Plus to combat the global TB epidemic.
QIAGEN will showcase the QIAseq xHYB
Mycobacterium tuberculosis Panel at the upcoming ESCMID Global 2024
(formerly known as ECCMID), which will be held in Barcelona, Spain,
from April 27 to April 30, 2024, at booth D20. Attendees can also
join the Diagnostic Insights series, featuring insights from
industry experts, and participate in demonstrations of diagnostic
technology such as the QIAcuityDx digital PCR platform, QIAstat-Dx
Analyzer 2.0, and QIAstat-Dx Rise. Additionally, a virtual reality
demo of the QIAstat-Dx Rise will be available. For more
information, please
visit: https://www.qiagen.com/us/applications/syndromic-testing/events-and-conferences/eccmid-inspiration
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
December 31, 2023, QIAGEN employed approximately 6,000 people
in over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, timing for launch
and development, marketing and/or regulatory approvals, financial
and operational outlook, growth and expansion, collaborations,
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, and its
impact on the demand for our products and other aspects of our
business, or other force majeure events; as well as the possibility
that expected benefits related to recent or pending acquisitions
may not materialize as expected; and the other factors discussed
under the heading “Risk Factors” contained in Item 3 of our most
recent Annual Report on Form 20-F. For further information, please
refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
[1] WHO Global Tuberculosis Report 2022,
https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-3-drug-resistant-tb
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Domenica Martorana
QIAGEN N.V.
+49 2103 29 11244
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024